Expression of WASF3 in patients with non-small cell lung cancer: Correlation with clinicopathological features and prognosis.

[wiskott-aldrich syndrome]

Wiskott-Aldrich syndrome protein family member 3 (WASF 3 ) is required for invasion and metastasis in different cancer cell types , and has been demonstrated to possess prognostic value in various types of human cancer . However , to the best of our knowledge , the expression profile of WASF 3 and its correlations with the clinicopathological features of non-small cell lung cancer (NSCLC ) have not yet been described . In the present study , the mRNA expression levels of WASF 3 , in 38 NSCLC patients and in matched normal tissues , were assessed using quantitative polymerase chain reaction and the protein expression in 96 specimens was analyzed using immunohistochemistry . In addition , patient survival data were collected retrospectively and the association between WASF 3 expression and five -year overall survival was evaluated . The results demonstrated that the mRNA expression level of WASF 3 in cancer tissues was markedly (approximately five times ) higher compared with that of the normal tissues . The WASF 3 protein expression profile in NSCLC was consistent with the mRNA expression result , which also correlated with the histological subtype and tumor stage . Furthermore , patients with WASF 3 -positive expression were associated with a poorer prognosis compared with those exhibiting WASF 3 -negative expression , and the five -year survival rate was 20 .8 and 46 .5 %, respectively (Kaplan-Meier ; log-rank , P =0 .004 ). In the multivariate analysis , which included other clinicopathological features , WASF 3 emerged as an independent prognostic factor (relative risk , 0 .463 ; 95 % CI , 0 .271 -0 .792 ). These results indicate that WASF 3 may be critical in the pathogenesis of NSCLC , in addition to being a valuable prognostic factor for NSCLC patients . Further investigations are required to identify the efficacy of WASF 3 as a potential therapeutic target for the treatment of NSCLC .

Diseases
Validation

Diseases presenting "five-year overall survival" symptom

wiskott-aldrich syndrome

You can validate or delete this automatically detected symptom